P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

被引:26
|
作者
Thuault, S. [1 ,2 ]
Hayashi, S. [3 ]
Lagirand-Cantaloube, J. [1 ,2 ]
Plutoni, C. [1 ,2 ]
Comunale, F. [1 ,2 ]
Delattre, O. [4 ]
Relaix, F. [3 ]
Gauthier-Rouviere, C. [1 ,2 ]
机构
[1] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[2] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[3] INSERM UPMC AIM, UMRS787, Paris, France
[4] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France
关键词
P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch; TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION;
D O I
10.1038/onc.2012.217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012
引用
收藏
页码:1876 / 1887
页数:12
相关论文
共 50 条
  • [31] The secreted Wnt inhibitor SFRP3 is required for PAX3-FOXO1-positive alveolar rhabdomyosarcoma tumorigenesis
    Kephart, Julie
    Jones, Rosanne
    Crose, Lisa
    Chi, Jen-Tsan Ashley
    Linardic, Corinne
    CANCER RESEARCH, 2014, 74 (20)
  • [32] Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
    Crose, Lisa E. S.
    Galindo, Kathleen A.
    Kephart, Julie Grondin
    Chen, Candy
    Fitamant, Julien
    Bardeesy, Nabeel
    Bentley, Rex C.
    Galindo, Rene L.
    Chi, Jen-Tsan Ashley
    Linardic, Corinne M.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (01): : 285 - 296
  • [33] PAX3-FOXO1 increases fibroblast reprogramming efficiency and drives self-renewal in alveolar rhabdomyosarcoma
    Schafer, Beat W.
    Casanova, Elisa
    Satheesha, Sampoorna
    Mueller, Melanie
    Cinelli, Paolo
    Cinelli, Paolo
    CANCER RESEARCH, 2014, 74 (19)
  • [34] PAX3-FOXO1 Induces Up-Regulation of Noxa Sensitizing Alveolar Rhabdomyosarcoma Cells to Apoptosis
    Marshall, Amy D.
    Picchione, Fabrizio
    Geltink, Ramon I. Klein
    Grosveld, Gerard C.
    NEOPLASIA, 2013, 15 (07): : 738 - +
  • [35] PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
    Jason A. Hanna
    Matthew R. Garcia
    Alicia Lardennois
    Patrick J. Leavey
    Dino Maglic
    Alexandre Fagnan
    Jonathan C. Go
    Jordan Roach
    Yong-Dong Wang
    David Finkelstein
    Mark E. Hatley
    Oncogene, 2018, 37 : 1991 - 2007
  • [36] PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
    Hanna, Jason A.
    Garcia, Matthew R.
    Lardennois, Alicia
    Leavey, Patrick J.
    Maglic, Dino
    Fagnan, Alexandre
    Go, Jonathan C.
    Roach, Jordan
    Wang, Yong-Dong
    Finkelstein, David
    Hatley, Mark E.
    ONCOGENE, 2018, 37 (15) : 1991 - 2007
  • [37] Targeting the chromatin architecture established by PAX3-FOXO1 in rhabdomyosarcoma
    Gryder, Berkley E.
    Yohe, Marielle E.
    Shern, Jack
    Chou, Hsien-Chao
    Song, Young
    Patidar, Rajesh
    Li, Sam
    Sindiri, Sivasish
    Cleveland, Abigail
    Liao, Hongling
    Wen, Xinyu
    Zhang, Xiaohu
    Mathews-Griner, Lesley
    Guha, Rajarshi
    Shinn, Paul
    Ferrer, Marc
    Martin, Scott
    Lal, Madhu
    Thomas, Craig
    Khan, Javed
    CANCER RESEARCH, 2016, 76
  • [38] Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma
    Jothi, Mathivanan
    Mal, Munmun
    Keller, Charles
    Mal, Asoke K.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (12) : 2663 - 2674
  • [39] PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome
    Teppei Ohkawa
    Akira Nishimura
    Kenjiro Kosaki
    Yuki Aoki-Nogami
    Daisuke Tomizawa
    Kenichi Kashimada
    Tomohiro Morio
    Motohiro Kato
    Shuki Mizutani
    Masatoshi Takagi
    Journal of Human Genetics, 2022, 67 : 51 - 54
  • [40] Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options
    J M Loupe
    P J Miller
    D R Ruffin
    M W Stark
    A D Hollenbach
    Oncogenesis, 2015, 4 : e145 - e145